Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
ZEISS Medical Technology and Boehringer Ingelheim announce today a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and more personalized...
In a move to better serve people living with and without diabetes, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will modernise their current alliance as of 1 January 2020 and focus its...
BURLINGTON, ON, May 27, 2019 /CNW/ - Results from a pivotal Phase III SENSCIS®® trial met its primary endpoint: reduction in the annual rate of decline in forced vital capacity (FVC1) in patients...
Data from secondary analyses of Phase III clinical trials showed that ABASAGLAR® (insulin glargine), Eli Lilly and Company and Boehringer Ingelheim's biosimilar insulin glargine, demonstrated safety...
Results from the LUX-Head & Neck 1 study show afatinib* significantly delayed tumour growth versus chemotherapy in patients following failure of their previous treatment, reducing the risk for...
Study shows antidote can lead to immediate, complete and sustained reversal of dabigatran-induced anticoagulation in healthy humans BURLINGTON, ON, Nov. 20, 2013 /CNW/ - Presented for the first time...
MONTREAL, June 27, 2013 /CNW Telbec/ - At a meeting coordinated in Montreal by cardiologist Dr. Thao Huynh of the McGill University Health Centre (MUHC), physicians and nurses from the 13 centres...
Data presented at the American Diabetes Association 73rd Scientific Sessions® also show statistically significant reductions in mean daily glucose and body weight in people with type 2 diabetes...
STARTVerso™1 data presented in treatment-naïve patients with genotype-1 hepatitis C treated with investigational faldaprevir and pegylated interferon/ribavirin1,2 Statistically significant viral cure ...
BURLINGTON, ON, Sept. 18, 2012 /CNW/ - Boehringer Ingelheim announced today that it will conclude its virology research programme, following a comprehensive review of its research areas and...
New program helps to break the ice and get Canadian adults and their parent(s) talking about a serious heart condition that can lead to stroke TORONTO, Aug. 7, 2012 /CNW/ - Many parents feels anxious ...
BURLINGTON, ON, June 26, 2012 /CNW/ - Findings published in Circulation demonstrate that treatment with PRADAX® (dabigatran etexilate) allows a substantially shorter interruption of oral...
Boehringer Ingelheim's investigational lung cancer treatment afatinib* prolongs progression free survival (PFS) for advanced non-small cell lung cancer patients with specific EGFR genetic mutations...
LUX-Lung 3 trial results highlighted at the official ASCO Press Conference: Afatinib* delays lung cancer progression compared to standard chemotherapy BURLINGTON, ON, June 4, 2012 /CNW/ - The...
PRADAX™ is a long awaited alternative for a quarter of a million Canadians at high risk of stroke due to atrial fibrillation (AF) TORONTO, Oct. 27 /CNW/ - Boehringer Ingelheim (Canada) Ltd. today...
Decision based on Canadian-led Trial from McMaster University TORONTO, Sept. 22 /CNW/ - The U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee on Monday voted 9 ...
New phase III data demonstrate clinically meaningful improvements in blood glucose control with linagliptin mono- and combination therapy INGELHEIM, GERMANY, June 28 /CNW/ - Linagliptin phase III...
- For Medical Media Only - BURLINGTON, ON, June 13 /CNW/ - Telmisartan, an angiotensin receptor blocker, is one of the best researched drugs worldwide. It has been studied in clinical trials in more...
BURLINGTON, ON, June 3 /CNW/ - Boehringer Ingelheim will present promising new data on non-small cell lung cancer as well as head-and-neck cancer for its leading investigational compound BIBW 2992*...
BURLINGTON, ON, May 19 /CNW/ - Significantly more pre-menopausal women with hypoactive sexual desire disorder (HSDD) reported a clinically meaningful improvement in their condition with flibanserin...
- Compared to well-controlled warfarin, dabigatran etexilate provided consistent benefits in stroke prevention in atrial fibrillation (AF), irrespective of a patient's risk profile...
Results from RE-COVER(TM) study published online in the New England Journal of Medicine(1) BURLINGTON, ON, Dec. 6 /CNW/ - Results from the landmark RE-COVER(TM) study were presented today at the...
New treatment option will reduce cardiovascular risk for the up-to-44 per cent of patients who cannot tolerate ACE inhibitors(1) ...
BURLINGTON, ON, Oct. 19 /CNW/ - Boehringer Ingelheim continues to be willing to provide WHO qualified generic pharmaceutical companies non assert declarations to manufacturer and export products...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.